Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India, a leader in advanced diagnostic imaging and healthcare technology, has installed and commissioned the Fujifilm Echelon Smart MRI at Jansons Health in Erode. The installation expands access to…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure